Objective-Vascular smooth muscle cell (SMC) proliferation has an indispensable role in the pathogenesis of vascular disease, but the mechanism is not fully elucidated. The epigenetic enzyme histone deacetylase 7 (HDAC7) is involved in endothelial homeostasis and SMC differentiation and could have a role in SMC proliferation. In this study, we sought to examine the effect of 2 HDAC7 isoforms on SMC proliferation and neointima formation. Methods and Results-We demonstrated that overexpression of unspliced HDAC7 (HDAC7u) could suppress SMC proliferation through downregulation of cyclin D1 and cell cycle arrest, whereas spliced HDAC7 (HDAC7s) could not. Small interfering RNA (siRNA)-mediated knockdown of HDAC7 increased SMC proliferation and induced nuclear translocation of ␤-catenin. Additional experiments showed that only HDAC7u could bind to ␤-catenin and retain it in the cytoplasm. Reporter gene assay and reverse transcription polymerase chain reaction revealed a reduction of ␤-catenin activity in cells overexpressing HDAC7u but not HDAC7s. Deletion studies indicated that the C-terminal region of HDAC7u is responsible for the interaction with ␤-catenin. However, the addition of amino acids to the N terminus of HDAC7u disrupted the binding, further strengthening our hypothesis that HDAC7s does not interact with ␤-catenin. The growth factor platelet-derived growth factor-BB increased the splicing of HDAC7 while simultaneously decreasing the expression of HDAC7u. Importantly, in an animal model of femoral artery wire injury, we demonstrated that knockdown of HDAC7 by siRNA aggravates neointima formation in comparison with control siRNA. Conclusion-Our findings demonstrate that splicing of HDAC7 modulates SMC proliferation and neointima formation through ␤-catenin nuclear translocation, which provides a potential therapeutic target in vascular disease. Key Words: HDAC Ⅲ beta catenin Ⅲ mouse model Ⅲ neointima Ⅲ smooth muscle V ascular smooth muscle cells (SMCs) are essential cellular components of blood vessels and play a pivotal role in the pathogenesis of arteriosclerosis. After vascular injury by risk factors, 1 various growth factors (eg, plateletderived growth factor [PDGF], transforming growth factor-␤) and cytokines (eg, interferon-␥) are released by different cell types (eg, endothelial cells, platelets, and monocytes). 2 This significantly promotes SMC proliferation that is indispensable to the formation of in-stent restenosis, transplant arteriosclerosis, and vein graft failure. 3 PDGF-BB release closely correlates with arteriosclerosis, probably because of its effects on SMC proliferation and migration. PDGF-BB binds and activates its receptor, PDGF receptor-␤. This initiates the activation of several pathways, including the extracellular signal-regulated kinase and phosphatidylinositol 3-kinase pathways. 4 However, the detailed mechanisms of the signaling pathways involved in SMC proliferation remain to be fully elucidated.
V ascular smooth muscle cells (SMCs) are essential cellular components of blood vessels and play a pivotal role in the pathogenesis of arteriosclerosis. After vascular injury by risk factors, 1 various growth factors (eg, plateletderived growth factor [PDGF] , transforming growth factor-␤) and cytokines (eg, interferon-␥) are released by different cell types (eg, endothelial cells, platelets, and monocytes). 2 This significantly promotes SMC proliferation that is indispensable to the formation of in-stent restenosis, transplant arteriosclerosis, and vein graft failure. 3 PDGF-BB release closely correlates with arteriosclerosis, probably because of its effects on SMC proliferation and migration. PDGF-BB binds and activates its receptor, PDGF receptor-␤. This initiates the activation of several pathways, including the extracellular signal-regulated kinase and phosphatidylinositol 3-kinase pathways. 4 However, the detailed mechanisms of the signaling pathways involved in SMC proliferation remain to be fully elucidated.
Histone deacetylases (HDACs) are a family of enzymes that remove acetyl groups from -N-acetylated lysine residues on histones. They are also reported to modulate cell proliferation. 5 Deacteylation of histones results in conformational changes to the chromatin structure, which usually results in the suppression of gene expression. 6 HDAC7 is a member of the class II HDACs and has been linked to cardiovascular diseases. [7] [8] [9] [10] [11] [12] [13] Several pioneering studies have demonstrated that HDAC7 plays a crucial role in early embryonic development, 7 angiogenesis, 8, 9 and SMC differentiation. 11 Moreover, HDAC7 can suppress endothelial cell proliferation 12 and responds to growth factors such as vascular endothelial growth factor and PDGF. 8 -12 However, the direct influence of HDAC7 on SMC proliferation has not yet been studied.
Pre-mRNA alternative splicing is a central mode of genetic regulation in higher eukaryotes. Variability in splicing patterns is a major source of protein diversity from the genome. 14 Recently, the importance of alternative splicing has drawn increasing attention in cardiovascular research. [15] [16] [17] Conventional splicing involves the excision of introns during premRNA processing, which leaves only exons in the mature mRNA. However, in certain cases, specific exons are spliced out or parts of an intron are conserved and expressed. 14, 18 These events lead to alternative primary amino acid sequences and can alter the conformation and binding partners of a protein.
␤-Catenin is both an adhesion molecule and a signal transducer of the Wnt pathway, which plays a critical role in SMC proliferation 19, 20 and arteriosclerosis. 21 ␤-Catenin promotes cell proliferation by inducing the transcription of ␤-catenin responsive genes 22 through activation of the T-cell factor (TCF)/lymphoid enhancer factor family of transcription factors. 23 ␤-Catenin predominantly localizes to the cellcell junctions. Cytoplasmic and nuclear levels of ␤-catenin are kept low by glycogen synthase kinase-3-mediated phosphorylation and subsequent degradation. 24 The stability and subcellular localization of ␤-catenin are pivotal in determining its function. However, the detailed mechanism controlling the nuclear-cytoplasmic shuttling event of ␤-catenin and any interactions with unspliced and spliced HDAC7 isoforms during SMC proliferation are not clear. We have recently found that HDAC7 interacts with ␤-catenin in endothelial cell. 12 In this study, we demonstrated that splicing of HDAC7 occurs in SMCs. In addition, the unspliced isoform is crucial for SMC proliferation and neointima formation by modulating the nuclear translocation of ␤-catenin.
Methods
SMCs were isolated by enzymatic digestion of mouse aortas (wildtype mice) as described elsewhere. 25, 26 SMCs were cultured in conditions as previously described. 26 -28 Small interfering RNA (siRNA) transfection (Supplemental Tables I to III, available online at http://atvb.ahajournals.org) and transient transfection procedures were similar to those reported before. 29 Cell proliferation assays were performed as previously described. 12, 30 All animal experiments were performed according to protocols approved by the Institutional Committee for Use and Care of Laboratory Animals, King's College London, UK. Femoral artery wire injury was performed as previously stated. 31 An expanded Materials and Methods section is available in the Supplemental Methods.
Results

Alternative Splicing of HDAC7 in Mice and Humans
Alternative splicing gives rise to numerous protein isoforms with different functions and is a common phenomenon in cardiovascular diseases. 15, 16, 32 We identified and studied 2 isoforms of HDAC7: unspliced HDAC7 (HDAC7u) and spliced HDAC7 (HDAC7s). The HDAC7s mRNA is 57 bp longer in the N-terminal region than HDAC7u mRNA (Supplemental Figure IA and Supplemental Tables IV and V) . We examined the genomic sequence surrounding the 57-bp fragment and found that directly adjacent are consensus 5Ј and 3Ј intron splice sites (Supplemental Figure IA and IIA) . Thus, we hypothesize that this fragment is a previously unreported cassette exon. 14, 33 To elucidate the function of both HDAC7 isoforms we subcloned HDAC7 cDNA to produce HDAC7u (deletion of the sequences before the second ATG site) and HDAC7s (deletion of the 57-bp sequence) plasmids. These were further subcloned into adenoviral DNA vectors. 11 A comparison of the major HDAC7 isoforms in mice (Supplemental Figure IB ) and humans (Supplemental Figure IC) revealed that a similar pattern of alternative splicing exists in the N terminus of human HDAC7 (Supplemental Figure ID) . Human HDAC7u protein shares 85% similarity with mouse HDAC7u protein (Supplemental Figure IIB) . It would be interesting to determine the reason for alternative splicing in the N terminus of HDAC7. We examined the expression of both HDAC7 isoforms in mouse aorta and cultured proliferating aortic vascular SMCs (Supplemental Figures IE and  IIID) . In animal aorta, the expression of HDAC7u and HDAC7s mRNA is almost equal, whereas in cultured SMCs HDAC7s is the dominant isoform detected. Furthermore, we found that HDAC7 mRNA (Supplemental Figure IIIA 
HDAC7u Suppresses SMC Proliferation
To identify the HDAC7 isoform involved in cell proliferation HDAC7u and HDAC7s were overexpressed in SMCs by adenoviral gene transfer at a multiplicity of infection of 5. Adenovirus (Ad)-tetracycline-controlled transactivatortreated and nontreated cells were used as controls. Overexpression of HDAC7u significantly suppressed SMC proliferation, as revealed by 5-bromo-2Ј-deoxyuridine incorporation assay ( Figure 1A Figure 1F ) and lowered cyclin D1 protein expression ( Figure 1D ). These results suggest that overexpression of the different HDAC7 isoforms has different impacts on SMC proliferation. Only HDAC7u is able to suppress SMC proliferation by downregulation of cyclin D1. 34 
Knockdown of HDAC7 Increases SMC Proliferation
Knockdown of HDAC7 significantly increased SMC proliferation compared with nontreated cells, as revealed by 5-bromo-2Ј-deoxyuridine incorporation (Figure 2A Importantly, both HDAC7u and HDAC7s could be significantly inhibited by siHDAC7 ( Figure 2F and Supplemental Figure III ). As expected, the protein level of cyclin D1 was increased in siHDAC7-treated cells ( Figure 2D ).
To elucidate the underlying mechanism, we performed double immunofluorescence staining of HDAC7 and ␤-catenin. Interestingly, in control siRNA-treated ( Figure  2G ) and untreated cells ( Figure 3D , bottom), HDAC7 localized to both the nucleus and the cytoplasm. In these cells, ␤-catenin localized to the pericellular junctions in most cells and to both the pericellular junctions and the nucleus in a small fraction of cells ( Figure 2G , top). In contrast, siRNAmediated knockdown of HDAC7 increased the fraction of cells containing ␤-catenin within the nucleus ( Figure 2G , bottom, and Supplemental VIE). A cell fraction experiment revealed more ␤-catenin in the nuclear fraction of siHDAC7-treated SMCs (Supplemental Figure VID and VIF). Real-time polymerase chain reaction (PCR) confirmed this finding as the ␤-catenin responsive genes, 22 such as cyclin D1, Axin2, Id2, Tcf3, and Tcf4, were upregulated on HDAC7 knockdown ( Figure 2H) . Cyclin D1 protein level was elevated, and there was no obvious change in ␤-catenin or active ␤-catenin level ( Figure 2D ). These results indicate that knockdown of HDAC7 increases SMC proliferation through increased nuclear translocation of ␤-catenin and upregulation of ␤-catenin responsive genes.
HDAC7u Binds to ␤-Catenin and Prevents Its Nuclear Localization
Having determined that knockdown of HDAC7 led to nuclear localization of ␤-catenin, we hypothesized that HDAC7 may directly interact with ␤-catenin in SMCs. To test this, we performed endogenous coimmunoprecipitation in SMCs. SMCs in the growth phase were lysed and precipitated with antibodies against HDAC7 and ␤-catenin. We found that HDAC7 directly binds to ␤-catenin ( Figure 3A and 3B), but not HDAC4 (Supplemental Figure VIIA) . We then asked whether both isoforms of HDAC7 can bind to ␤-catenin with the same affinity, because only HDAC7u is able to suppress SMC proliferation. Interestingly, ␤-catenin was only detectable in the human influenza hemagglutinin (HA) immunoprecipitate after overexpression of HDAC7u ( Figure 3C ), whereas 14-3-3 was detectable in both HDAC7u and HDAC7s precipitate (Supplemental Figure VB) . This indicates that only HDAC7u could bind to ␤-catenin in SMCs.
We subsequently performed double immunofluorescence staining of HA and ␤-catenin to determine the cellular location of both HDAC7 isoforms and ␤-catenin. Endogenous HDAC7 localized to both the cytoplasm and the nucleus, whereas ␤-catenin was found predominantly in the pericellular area ( Figure 3D ). HA staining demonstrated that HDAC7s was present in both the nucleus and the cytoplasm, whereas HDAC7u was located exclusively in the cytoplasm. We also demonstrated colocalization of HDAC7u and ␤-catenin. In Ad-HDAC7u-infected cells, ␤-catenin was barely detectable in the nucleus ( Figure 3D and Supplemental Figure VIB), whereas there was no obvious change in ␤-catenin localization in Ad-HDAC7s-infected SMCs. Cell fraction assay confirmed the localization of HDAC7 isoforms and showed less ␤-catenin in the nuclear fraction in HDAC7u overexpressing SMCs (Supplemental Figure VIA and VIC) . Active ␤-catenin 12 increased, with no significant change in total ␤-catenin level ( Figure 1D ). Furthermore, using a TOPflash/FOPflash reporter assay, we revealed that reduced luciferase activity was induced by the TCF/lymphoid enhancer factor binding site in SMCs cotransfected with HDAC7u ( Figure 3E ). This indicates reduced nuclear localization of ␤-catenin. 35 As expected, real-time PCR confirmed that overexpression of HDAC7u downregulated the expression of the ␤-catenin-responsive genes cyclin D1, Axin2, Tcf3, and Tcf4 ( Figure 3F ). In summary, these results suggest that HDAC7u and HDAC7s function differently because of their different binding affinities with ␤-catenin. Specifically, only HDAC7u can bind to ␤-catenin and retain it in the cytoplasm.
Identification of the HDAC7 Binding Site With ␤-Catenin
After confirming the interaction between HDAC7u and ␤-catenin, we wanted to identify the region of HDAC7u that is responsible. The sole difference between HDAC7u and HDAC7s is the additional 22 N-terminal amino acids of HDAC7s. We therefore hypothesized that the binding site responsible for the interaction with ␤-catenin is present in the N-terminal region of HDAC7u. We produced several deletion mutants of HDAC7u which involved deleting different lengths in the N terminus (D1 to D4) and deletion of the C terminus (D5) ( Figure 4A ). Cotransfection of D1 to D5 alongside Flag-tagged mouse ␤-catenin in HEK-293 cells indicated that D1 to D4 retained the ability to bind ␤-catenin, whereas D5 lost this ability. Surprisingly, this identifies the ␤-catenin binding site to the C-terminal region. If the ␤-catenin binding site is present in the C terminus, how is it possible that alteration of the N-terminal region affects this interaction?
To shed some light on this conundrum, we produced a deletion mutant lacking the first 15 N-terminal amino acids of HDAC7s, which has the same effect as adding an additional 7 amino acids to the N terminus of HDAC7u (D6). A second deletion mutant, lacking amino acids 23 to 178 of HDAC7s, was also produced (D7). This mutation added the 22 N-terminal amino acids of HDAC7s to the D1 mutant. As revealed by HA-antibody-mediated immunoprecipitation, the D6 mutation lost the ability to bind ␤-catenin, whereas the D7 mutation did not ( Figure 4B and Supplemental Figure VIII) . These experiments reveal that HDAC7 interacts with ␤-catenin through a C-terminal site. However, additional amino acids in the N terminus can disrupt this interaction because the D6 mutation does not bind to ␤-catenin. Because HDAC7-D4, which lacks amino acids 1 to 601 in the N terminus of HDAC7u, could still bind to ␤-catenin, we hypothesized that HDAC7-D4 could have the same effect as HDAC7u on SMC proliferation. The constructs were transfected by nucleofection, and 5-bromo-2Ј-deoxyuridine incorporation was measured as an indication of cell proliferation. HDAC7-D4 and HDAC7u both significantly suppressed SMC proliferation to a similar level, whereas HDAC7-D5 had no effect ( Figure 4C ). These results provide strong evidence that HDAC7 affects SMC proliferation through modulation of ␤-catenin.
PDGF-BB Increases HDAC7 Splicing
PDGF-BB is a potent stimulator of SMC migration, as well as proliferation, but the mechanism through which PDGF-BB enhances SMC proliferation is not fully understood. 36 In contrast to HDAC7s, HDAC7u can suppress SMC proliferation. We hypothesized that PDGF-BB could modulate the ratio of HDAC7u to HDAC7s. There is no antibody currently available that can distinguish between the 2 protein isoforms of HDAC7; therefore, we used reverse transcription PCR to detect the mRNA level of the endogenous HDAC7 isoforms. We have previously found that PDGF-BB increases the promoter activity of HDAC7 and promotes its transcription. 11 In this study, we used actinomycin D to inhibit transcription. Treatment of SMCs with PDGF-BB (10 ng/mL) for 30 minutes significantly increased HDAC7s expression ( Figure   5A ). Using primers specific for HDAC7u, we showed that HDAC7u expression decreased after PDGF treatment, whereas the total level of HDAC7 mRNA was unaffected ( Figure 5B ). We then performed Western blot analysis to examine the effect of PDGF-BB on HDAC7 splicing at the protein level. The construct of full-length HDAC7 adenovirus was described previously 11 (Supplemental Figure IIC) . As expected, PDGF-BB significantly increased the expression of HDAC7s at the protein level ( Figure 5C ). After 6 hours of PDGF-BB (10 ng/mL) treatment, there was a significant upregulation in the Flag:HA ratio ( Figure 5D ), with no obvious change in the total HA or HDAC7 protein levels. Furthermore, PDGF could abolish genomic HDAC7's effect on SMC proliferation (Supplemental Figure IX) . These results provide solid evidence that PDGF-BB increases HDAC7 splicing in SMCs and offers a novel pathway responsible for PDGF stimulated SMC proliferation.
HDAC7 siRNA Aggravates Neointima Formation in Injured Arteries
To examine whether the role of HDAC7 in SMC proliferation has relevance to disease models, we performed in vivo experiments to examine the role of HDAC7 during neointima formation. HDAC7 siRNA and control siRNA were mixed with pluronic gel-127 and delivered to the adventitial side of injured vessels to assess the effect of HDAC7 knockdown on neointimal formation after endothelial denudation. Previously, a high efficiency of transfection was achieved with pluronic gel containing siRNA that was perivascularly applied to wire-injured artery. 37 Two weeks after the operation, the arteries were harvested, fixed, sectioned, and stained with hematoxylin and eosin. Real-time reverse transcription PCR demonstrated that the HDAC7 mRNA and protein levels in HDAC7 siRNA-treated femoral artery were significantly lower than those of the control siRNA-treated arteries (Supplemental Figure X) , indicating successful in vivo knockdown. HDAC7 siRNA aggravated neointima formation ( Figure 6A ). Quantitative analysis and statistics also confirmed this observation ( Figure 6B and 6C) . Furthermore, we performed proliferation marker Ki67 staining in the arteries 14 days after injury (Supplemental Figure XI) and found significantly increased proliferating cells in intima of siHDAC7-treated arteries. Quantification of reendothelialization revealed no difference in both groups (Supplemental Figure XII) . Seven days after injury, we performed HDAC7 and ␤-catenin double immunofluorescent staining. As indicated in Supplemental Figure XA , there were more cells with nuclear ␤-catenin localization in siHDAC7-treated arteries (Supplemental Figure XB) . Cyclin D1 protein and mRNA levels were also elevated in siHDAC7-treated arteries (Supplemental Figure XC and  XD) . These results highlight the crucial role of HDAC7 during the pathogenesis of restenosis, which may result from its impact on SMC proliferation.
Discussion
This study sheds light on the functional importance of N-terminal alternative splicing of HDAC7 in modulating SMC proliferation and neointima formation. First, we demonstrated that N-terminal alternative splicing of HDAC7 is a common phenomenon in both mice and humans. Second, we found that HDAC7s and HDAC7u have different impacts on SMC proliferation in mice, which is due to distinct binding affinities with ␤-catenin. Furthermore, we identified that HDAC7 interacts with ␤-catenin through a C-terminal binding site, although N-terminal amino acids play a crucial role in regulation of this interaction. The careful balance between HDAC7s and HDAC7u can be influenced by the growth factor PDGF-BB (Supplemental Figure XIII) . Finally, siRNAmediated knockdown of HDAC7 promoted SMC proliferation in vitro and aggravated neointima formation in vivo. Our findings provide a novel mechanistic insight into SMC proliferation and identify a signaling pathway that could be a potential target for disrupting cell growth and a key event during restenosis. involve deletions of the N terminus of unspliced HDAC7 (HDAC7u), whereas D5 lacks the C terminus. D6 and D7 were produced from the spliced HDAC7 (HDAC7s) plasmid. D6 deletes the first 15 N-terminal amino acids (AA) of HDAC7s. D7 deletes amino acids 23 to 178 of HDAC7s, which has the same effect as adding the first 22 amino acids of HDAC7s to the D1 construct. All plasmids were verified by sequencing. B, HEK-293 cells were cotransfected with human influenza hemagglutinin (HA)-tagged HDAC7 deletions alongside Flag-tagged mouse ␤-catenin. Whole cell lysates were subjected to HA immunoprecipitation (IP) 48 hours after transfection. Each deletion mutant was expressed in HEK-293 cells, as demonstrated by the detection of HA in the precipitates and input ( Supplemental Figure V) . All the deletion mutants except D5 and D6 showed specific binding with Flag-tagged ␤-catenin. C, 5-Bromo-2Ј-deoxyuridine (BrdU) incorporation assay (48 hours after nucleofection) showed that HDAC7-D4 but not HDAC7-D5 can suppress smooth muscle cell (SMC) proliferation to a similar level as HDAC7u. *PϽ0.05 compared with vector transfection. nϭ3 in B, nϭ4 in C.
Alternative splicing determines the inclusion of a portion of coding sequence in mRNA and can give rise to protein isoforms that differ in their peptide sequence and biological activity. 14 It is estimated that the minimum number of human gene products that undergo alternative splicing is 60%. 38 Cassette exons, a common form of alternative splicing, are not always present in mature mRNA, as they can either be included or spliced out. 14, 18 Our previous studies have revealed that in mouse embryonic stem cells, there is an additional 57 bp exon located in introns 1 to 2 of HDAC7. 11 This 57-bp sequence contains 3 stop codons that halt transcription from the first start codon (ATG) (Supplemental Figure IA) . A shorter protein product, HDAC7u, is produced as transcription subsequently initiates from a second ATG site. However, as stem cells differentiate into SMCs, the expression of the spliced isoform of HDAC7 increases. 11 This isoform lacks the 57-bp exon, allowing transcription to initiate from the first ATG site, giving rise to a protein containing 22 additional amino acids at the N terminus (HDAC7s) (Supplemental Figure IA) . The consensus 5Ј and 3Ј splice sites contain GU (intron start) and AG (intron end) ribonucleosomes, respectively. 33 Here we have identified a possible 57-bp exon contained within the 19.7-kb introns 1 to 2 of the mouse HDAC7 gene (Supplemental Figure IIA) . Deletion mutant studies identified that the N-terminal region is crucial in determining the binding affinity of HDAC7 toward ␤-catenin. Interestingly, this N-terminal splicing event also occurs in human HDAC7. Human HDAC7s protein is 39 amino acids longer than its unspliced counterpart. Unspliced human and mouse HDAC7 have highly homologous N-terminal and C-terminal sequences (Supplemental Figure IIB) . Thus, we speculated that mouse HDAC7u would be functional in human SMCs. Adenovirus-mediated overexpression of mouse HDAC7u significantly suppressed human SMC proliferation, whereas mouse HDAC7s had no effect (Supplemental Figure XIVA and XIVB) . Downregulation of cyclin D1 occurred only after overexpression of HDAC7u (Supplemental Figure XIVC) . We reasoned that mouse HDAC7 is functional in human SMCs because of its ability to bind to human ␤-catenin (Supplemental Figure  XIVD) . The HDAC7 investigated in human endothelial cells 12 is similar to human HDAC7u. These results indicate that our findings in mice could largely be translated into human conditions. HDAC7 is a member of the class II HDACs, which are characterized by an extended N-terminal regulatory domain. The function of this domain is not clear. Our results clearly show that the N terminus of HDAC7 is not responsible for the interaction with ␤-catenin (Figure 4) . However, when 7 amino acids were added to the N terminus of HDAC7u (HDAC7-D6), the binding between HDAC7 and ␤-catenin was abolished. HDAC7-D7, involving the addition of 22 amino acids to the N terminus of HDAC7-D1, allowed us to assess whether additional N-terminal amino acids are sufficient to disrupt the interaction with ␤-catenin. As indicated in Figure 4B , HDAC7-D7 was still able to bind to ␤-catenin, implying that the exact sequence of the additional amino acids is not specific. Although the 3-dimensional structure of the HDAC7 protein is not yet available, it is possible that the N-terminal region of HDAC7 is spatially adjacent to the C-terminal site, which mediates the binding of HDAC7 to ␤-catenin. Additional amino acids in the N-terminal region might exclude ␤-catenin from the binding site, thus inducing a loss of function.
PDGF-BB activates various signal pathways and promotes SMC proliferation, 4 but the mechanism is not entirely clear. Several groups discovered that PDGF-BB-induced proliferation of SMCs and fibroblasts requires HDAC activity. 39, 40 In this study, we found that PDGF-BB induces HDAC7 splicing, leading to an increase in HDAC7s levels while decreasing HDAC7u levels. As HDAC7u suppresses SMC proliferation, the role of PDGF-BB in promoting HDAC7 splicing might be a novel mechanism through which PDGF-BB exerts its function during SMC proliferation. Another interesting finding is that the ratio of HDAC7s:HDAC7u is different between aorta and cultured cells. HDAC7s is the dominant isoform in proliferating cells (Supplemental Figure IE) . However, in normal mouse aorta, HDAC7u is almost as abundant as HDAC7s. Proliferating SMCs have lower expression of HDAC7u compared with quiescent SMCs, as well as cells from mouse aorta, indicating a physiological relevance between HDAC7u and SMC proliferation.
As described above, SMCs are mostly in a quiescent phase in normal vessels and only became proliferative in response to endothelial injury, which is a key event in the development of restenosis. 41 Here, we used an in vivo mouse injury model and found that siRNA-mediated knockdown of HDAC7 aggravates neointimal formation. Additional experiments reasoned that the increased proliferating cells but not the difference in reendothelialization was responsible for the increased neointima formation. Immunofluorescent staining revealed increased nuclear translocation of ␤-catenin in siHDAC7-treated arteries, with elevated cyclin D1 mRNA and protein levels. These findings indicate that HDAC7 plays a crucial role in mediating SMC proliferation in vivo.
In summary, the growth factor PDGF can induce SMC proliferation in which HDAC7 exerts its role in signal pathways leading to gene expression. HDAC7 is normally maintained as an unspliced isoform in cytoplasm, where it binds to ␤-catenin and keeps SMCs in a quiescent state. After PDGF stimulation HDAC7 is spliced and no longer binds to ␤-catenin. The released ␤-catenin translocates to the nucleus and binds to TCF to activate gene expression related to cell proliferation (Supplemental Figure XIII) . Thus, these findings suggest that HDAC7 might be a promising therapeutic target in atherosclerosis, in particular prompting investigation of whether certain molecules (eg, nitric oxide) could modulate HDAC7 splicing process would be beneficial. 
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None. Figure 6 . Histone deacetylase 7 (HDAC7) small interfering RNA (siRNA) aggravates neointima formation in injured arteries. A, Representative images of noninjured artery, control small interfering RNA (ctl siRNA), and siRNA targeted against HDAC7 (siHDAC7)-intervened femoral arteries. Fourteen days after the application of the siRNA, the mice were euthanized, and their arteries were harvested, fixed, sectioned, and stained with hematoxylin and eosin. Original magnification ϫ100 (a to c), ϫ400 (d to f). B and C, Quantitative data of neointima (B) and ratio of neointima/media (C) in ctl siRNA and siHDAC7-treated groups. Data are meansϮSEM (nϭ5/group). Arrows indicate neointima. *PϽ0.05 compared with ctl siRNA.
